The DOCK11 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered from the NCI-H1299 human lung carcinoma cell line, designed for loss-of-function studies of the DOCK11 gene. This polyclonal model disrupts DOCK11 across a heterogeneous cell pool, providing a robust system for functional genomics without clonal artifacts.
NCI-H1299 is a well-established epithelial cell line derived from a lymph node metastasis of non-small cell lung cancer (NSCLC), widely used to study tumor progression, metastasis, and drug responses. Its tumorigenic background makes it a relevant host for investigating the role of DOCK11 in lung cancer biology, particularly in cytoskeletal reorganization and invasive behavior.
DOCK11 encodes a guanine nucleotide exchange factor (GEF) for the small GTPases Cdc42 and Rac. Upon activation by upstream signals such as cytokine receptors (e.g., IL-15R), integrins, and PI3K, DOCK11 associates with ELMO adaptor proteins (ELMO1, ELMO2, ELMO3) to catalyze GDP/GTP exchange on Cdc42 and Rac. These activated GTPases then stimulate effectors like PAK1, the WAVE complex, and the ARP2/3 complex, culminating in actin filament nucleation and lamellipodia formation. This pathway governs cell migration, adhesion, and immune cell functions, and is modulated by Src family kinases and receptor tyrosine kinases.
Disrupting DOCK11 in NCI-H1299 cells is anticipated to impair Cdc42/Rac-driven actin dynamics, reducing migration, invasion, and adhesion??processes critical for NSCLC metastasis. The knockout model offers a platform to dissect how DOCK11 contributes to the metastatic phenotype and to test its involvement in tumor-microenvironment interactions. Furthermore, it enables exploration of potential synthetic lethal relationships or drug sensitivities in lung cancer cells lacking DOCK11 activity.
Key applications include wound healing and transwell migration assays to assess motility, phalloidin staining for actin visualization, and Rho GTPase activation assays or western blotting for Cdc42/Rac activity. Co-immunoprecipitation can verify DOCK11-ELMO interactions, while proliferation assays and RNA-seq provide broader phenotypic and transcriptomic readouts. This product supports target validation in NSCLC and cancer metastasis, investigation of cytoskeletal signaling, and functional studies of DOCK11 in hematopoietic disorders and immune dysregulation. For additional information or custom services, contact Ascent Research.
